Paxlovid fails to improve long COVID symptoms in small study

Paxlovid fails to improve long COVID symptoms in small study Using the popular COVID antiviral Paxlovid failed to significantly improve symptoms in 155 patients experiencing moderate to severe long COVID, according to a study published today in JAMA Internal Medicine.  CIDRAP

...

The findings are part of the STOP-PASC trial, and the study was conducted at Stanford University from November 2022 to September 2023. All enrollees reported at least 3 months of postacute sequelae of SARS-CoV-2 infection (PASC) symptoms.

...